Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Banks to seek competing bid for Rs 729-cr Sahara Star Hotel debt
8/10/2025
Dotcom fears rise with tech stocks seeing $100-billion swings
8/10/2025
Is it the right time to invest in Nifty Private Bank index ?
8/10/2025
How will RBI's new ECL framework impact lending practices ?
8/10/2025
Nifty 50 companies poised for double-digit net profit growth for fourth consecutive quarter
8/10/2025
Vijay Kedia buys on dips, acquires Rs 11 crore stake in smallcap company via bulk deal
7/10/2025
